Pathogenesis and Emerging Targeted Therapies in Myeloproliferative Neoplasms – NEJM Group
NEJM Group shared a post on LinkedIn about a recent article by Isabelle Plo and William Vainchenker, adding:
“A new review summarizes the pathogenesis and treatment of myeloproliferative neoplasms, highlighting the role of driver mutations, inflammation, and emerging targeted therapies that may achieve durable disease modification.
Classic myeloproliferative neoplasms, including essential thrombocythemia, polycythemia vera, and primary myelofibrosis, are chronic, clonal hematopoietic stem-cell disorders.
These disorders are driven by gain-of-function mutations in the genes Janus kinase 2 (JAK2), calreticulin (CALR), or the thrombopoietin receptor (MPL) that activate cytokine signaling.
These mutations arise decades before clinical disease develops and confer a clonal advantage that is further shaped by comutations in epigenetic, splicing, or signaling genes.
Inflammation enhances clonal dominance, favoring the development of myelofibrosis and thrombotic complications.
Disease evolution may culminate in secondary acute myeloid leukemia, which has a poor prognosis.
Current therapies primarily aim to control symptoms, thrombosis, and splenomegaly, but they have limited disease-modifying effects, except for pegylated interferon alfa and JAK2 inhibitors in some patients.
Emerging therapies that selectively target mutant CALR and JAK2 V617F using immunotherapy and selective inhibitors could be a breakthrough in the treatment of persons with myeloproliferative neoplasms, with the expectation of achieving durable disease modification and potentially clonal eradication.”
Title: Myeloproliferative Neoplasms
Authors: Isabelle Plo, William Vainchenker
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 25, 2026, 17:31Kasimu Hussaini: Blood Component Therapy From Whole Blood to Targeted Treatment
-
Oct 25, 2026, 17:23Zahra Safarzadeh: When Low Factor VII Activity and Reduced VWF Antigen Coexist
-
Oct 25, 2026, 17:17Anubhav Joshi: Evans Syndrome in CLL A Differential Diagnosis to Remember
-
Oct 25, 2026, 17:04Tehila Alter: Tracking Hematopoietic Cell Engraftment in Bone Marrow Using CEST MRI
-
Oct 25, 2026, 16:45Shauna RileyÖ‰ First Guidelines for Hemoglobin SC Disease
-
Oct 25, 2026, 16:26Heghine Khachatryan: Patient Safety and Clinical Judgment in Platelet Transfusion Decisions
-
Oct 25, 2026, 16:13Funmi (Vanessa) Ullam: From Lived Experience to Research and Innovation in Sickle Cell Care
-
Oct 25, 2026, 15:13Franky Biles: Celebrating Diversity and Driving Inclusion Through Representation
-
Oct 25, 2026, 14:47Siddharth Mittal: A Sheet-Like Effluent Deposit During Plasma Exchange in iTTP